Fetal therapy for Down syndrome: an ethical exploration

Prenatal Diagnosis

Volumn 37, Issue 3, 2017, Pages 222-228

  de Wert, Guido ^a   Dondorp, Wybo ^a   Bianchi, Diana W ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COGNITION; COGNITIVE THERAPY; DISABILITY; DOWN SYNDROME; FETAL THERAPY; FETUS; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MEDICAL ETHICS; NONHUMAN; PARENTAL ATTITUDE; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; ETHICS; FEMALE; MOUSE; NEWBORN; PHYSIOLOGY; PREGNANCY; PROCEDURES; PSYCHOLOGY;

ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FETAL THERAPIES; HUMANS; INFANT, NEWBORN; MICE; PREGNANCY;

EID: 85011665656     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4995     Document Type: Article

References (46)

1. Gil MM, Quezada MS, Revello R, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45(3):249–66.
2. Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open 2016;6(1e010002).
3. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370(9):799–808.
4. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372(17):1589–97.
5. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012;18(7):1041–1051.
6. Stagni F, Giacomini A, Guidi S, et al. Timing of therapies for Down syndrome: the sooner, the better. Front Behav Neurosci 2015;9:265.
7. Newton RW, Puri S, Marder L. Down Syndrome. Current Perspectives. Mac Keith Press: London; 2015.
8. Bull MJ. Committee on G. Health supervision for children with Down syndrome. Pediatrics 2011;128(2):393–406.
9. Santoro SL, Martin LJ, Pleatman SI, et al. Stakeholder buy-in and physician education improve adherence to guidelines for Down syndrome. J Pediatr 2016;171262-8 e1-2.
10. Guedj F, Bianchi DW, Delabar JM. Prenatal treatment of Down syndrome: a reality? Curr Opin Obstet Gynecol 2014;26(2):92–103.
11. Jiang J, Jing Y, Cost GJ, et al. Translating dosage compensation to trisomy 21. Nature 2013;500(7462):296–300.
12. Sample I. Down's syndrome cells 'fixed' in first step towards chromosome therapy. Guardian. 2013 13 July.
13. Bahado-Singh RO, Wyse L, Dorr MA, et al. Fetuses with Down syndrome have disproportionately shortened frontal lobe dimensions on ultrasonographic examination. Am J Obstet Gynecol 1992;167(4 Pt 1):1009–14.
14. Rotmensch S, Goldstein I, Liberati M, et al. Fetal transcerebellar diameter in Down syndrome. Obstet Gynecol 1997;89(4):534–7.
15. Tarui T, Madan N, Madankumar R, et al. Advanced magnetic resonance imaging of the developing brain in living fetuses with Down syndrome. Prenat Diagn 2015;(35 Suppl. 1abstract 3-2):7.
16. Slonim DK, Koide K, Johnson KL, et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci U S A 2009;106(23):9425–9.
17. Guedj F, Bianchi DW. Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome. Prenat Diagn 2013;33(6):614–8.
18. Ralston SJ, Wertz D, Chelmow D, et al. Pregnancy outcomes after prenatal diagnosis of aneuploidy. Obstet Gynecol 2001;97(5 Pt 1):729–33.
19. Guidi S, Stagni F, Bianchi P, et al. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Brain 2014;137(Pt 2):380–401.
20. Stagni F, Giacomini A, Guidi S, et al. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Neurobiol Dis 2015;74:204–18.
21. Rochman B. Parents turn to Prozac to treat Down syndrome. MOT Technology review. 2016.
22. Guedj F, Pennings JL, Massingham LJ, et al. An integrated human/murine transcriptome and pathway approach to identify prenatal treatments for Down syndrome. Sci Rep 2016;6:32353.
23. Inglis A, Lohn Z, Austin JC, et al. A 'cure' for Down syndrome: what do parents want? Clin Genet 2014;86(4):310–7.
24. Solomon A. Far from the tree. Parents, children and the search for identity. Scribner: New York; 2012.
25. Glover J. Choosing Children. The Ethical Dilemmas of Genetic Intervention. Oxford University Press: Oxford; 2006.
26. Nussbaum M. The capabilities of people with cognitive disabilities. Metaphilosophy 2009;40(3-4):331–51.
27. Skotko BG, Levine SP, Goldstein R. Having a son or daughter with Down syndrome: perspectives from mothers and fathers. Am J Med Genet A 2011;155A(10):2335–47.
28. Buchanan A, Brock DW, Daniels N, et al. From Chance to Choice. Genetics & Justice. Cambridge University Presss: Cambridge; 2000.
29. Shakespeare T. Disability Rights and Wrongs Revisited, Second ed. Routledge: London & New York; 2014.
30. Davis DS. Genetic Dilemmas: Reproductive Technology, Parental Choices, and Children's Futures, Second ed. Oxford University Press: Oxford; 2010.
31. Parens E, Asch A. Disability rights critique of prenatal genetic testing: reflections and recommendations. Ment Retard Dev Disabil Res Rev 2003;9(1):40–7.
32. Neri G, Opitz JM. Down syndrome: comments and reflections on the 50th anniversary of Lejeune's discovery. Am J Med Genet A 2009;149A(12):2647–54.
33. Epstein CJ, Cox DR, Schonberg SA, et al. Recent developments in the prenatal diagnosis of genetic diseases and birth defects. Annu Rev Genet 1983;17:49–83.
34. deJong A, deWert GM. Prenatal screening: an ethical agenda for the near future. Bioethics 2015;29(1):46–55.
35. Dondorp W, deWert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015;23(11):1438–50.
36. vanSchendel RV, Kleinveld JH, Dondorp WJ, et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet 2014;22(12):1345–50.
37. Howe EG. Ethical issues in fetal surgery. Semin Perinatol 2003;27(6):446–57.
38. Sheppard M, Spencer RN, Ashcroft R, et al. Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction. Ultrasound Obstet Gynecol 2016;47(4):484–91.
39. Noble R, Rodeck CH. Ethical considerations of fetal therapy. Best Pract Res Clin Obstet Gynaecol 2008;22(1):219–31.
40. Health Council of the Netherlands. Care for the unborn child. Ethical and legal aspects of fetal therapy. The Hague; 2009.
41. Deprest J, Toelen J, Debyser Z, et al. The fetal patient -- ethical aspects of fetal therapy. Facts Views Vis Obgyn 2011;3(3):221–7.
42. Paterson L, McKenzie K, Lindsay B. Stigma, social comparison and self-esteem in adults with an intellectual disability. J Appl Res Intellect Disabil 2012;25(2):166–76.
43. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011;364(11):993–1004.
44. Murray TH. Moral obligations to the not-yet born: the fetus as patient. Clin Perinatol 1987;14(2):329–43.
45. Nuffield Council on Bioethics. Critical care decisions in fetal and neonatal medicine: ethical issues. London; 2006.
46. Savulescu J. Future people, involuntary medical treatment in pregnancy and the duty of easy rescue. Utilitas 2007;19(1):1–20.